WHAT IS A
BIOSIMILAR?
Biosimilars are biologic
medicines that are highly
similar to and have no clinically
meaningful differences from an
already approved biologic
known as the reference
medicine.
Reference medicines are existing medicines or treatments that are already available and approved, against which a biosimilar is compared.
All FDA-approved biosimilars are extensively evaluated to ensure that patients can rely on their efficacy, safety, and quality.
WHAT IS THE DIFFERENCE BETWEEN A BIOSIMILAR AND A GENERIC DRUG?
There are key differences between a biosimilar and a generic drug.
Generic drugs’ active ingredients match those used in brand name drugs while biosimilars must demonstrate that the biosimilar is highly similar* with no clinically meaningful differences in both safety and effectiveness.
*“Highly similar” means there may be a slight difference between a reference product and a biosimilar product in clinically inactive components (parts that do not meaningfully impact important product features such as safety or efficacy) - this is acceptable for FDA approval.